Related Experiment Video

Updated: May 4, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

7.0K

Novel taxanes

Franco Muggia1, David Kudlowitz

  • 1NYU Cancer Institute, New York, New York, USA.

Anti-Cancer Drugs
|December 31, 2013
PubMed

Insights

New taxane formulations, including novel analogs and immunotoxins, aim to enhance cancer treatment efficacy and reduce toxicity. These advanced chemotherapy drugs are under investigation for various cancer types.

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Development

Background:

  • Paclitaxel, a key chemotherapy agent, has seen numerous new formulations since the 1990s.
  • Next-generation taxanes are being developed to improve efficacy, reduce toxicity, and overcome drug resistance.
  • Innovations include new analogs and immunotoxins targeting cancer cells more specifically.

Purpose of the Study:

  • To review the development and clinical efficacy of novel taxane formulations.
  • To highlight advancements in chemotherapy aimed at improving cancer treatment outcomes.
  • To discuss the potential of next-generation taxanes and immunotoxins in oncology.

Main Methods:

  • Review of clinical studies and scientific literature on taxane derivatives.
  • Analysis of new taxane formulations, including cabazitaxel, paclitaxel poliglumex, and immunotoxins.
  • Examination of ongoing phase II and III trials for various cancer types.

Main Results:

  • Several new taxane formulations like cabazitaxel and paclitaxel poliglumex demonstrate clinical efficacy.
  • Immunotoxins such as trastuzumab emtansine show increased cytotoxicity and specificity.
  • Ongoing studies are evaluating these advanced chemotherapeutics across diverse cancers.

Conclusions:

  • Novel taxane formulations and immunotoxins represent significant advancements in cancer therapy.
  • These agents offer improved therapeutic profiles, targeting cancer cells more effectively.
  • Further research and clinical trials are crucial for optimizing their use in oncology.

More Related Videos

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice08:41

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

22.6K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.0K

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.2K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
820